​
​

Carisma Therapeutics (CARM) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChart

CARM Stock Forecast

Carisma Therapeutics stock forecast is as follows: an average price target of $6.00 (represents a 591.96% upside from CARM’s last price of $0.87) and a rating consensus of 'Buy', based on 3 wall street analysts offering a 1-year stock forecast.

CARM Price Target

The average price target for Carisma Therapeutics (CARM) is $6.00 based on 1-year price targets from 3 Wall Street analysts in the past 3 months, with a price target range of $6.00 to $6.00. This represents a potential 591.96% upside from CARM's last price of $0.87.

CARM Analyst Ratings

Buy

According to 3 Wall Street analysts, Carisma Therapeutics's rating consensus is 'Buy'. The analyst rating breakdown for CARM stock is 0 'Strong Buy' (0.00%), 3 'Buy' (100.00%), 0 'Hold' (0.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).

Carisma Therapeutics Price Target by Analyst

DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Apr 11, 2024Justin ZelinBTIG$6.00$1.91214.14%591.96%
Row per page
Go to

The latest Carisma Therapeutics stock forecast, released on Apr 11, 2024 by Justin Zelin from BTIG, set a price target of $6.00, which represents a 214.14% increase from the stock price at the time of the forecast ($1.91), and a 591.96% increase from CARM last price ($0.87).

Carisma Therapeutics Price Target by Period

1M3M12M
# Anlaysts--1
Avg Price Target--$6.00
Last Closing Price$0.87$0.87$0.87
Upside/Downside-100.00%-100.00%591.96%

In the current month, the average price target of Carisma Therapeutics stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Carisma Therapeutics's last price of $0.87. This month's average price target is down NaN% compared to last quarter, and down -100.00% compared to last year.

Analyst Ratings Upgrades/Downgrades

DateCompanyPrevious RatingNew RatingRating Change
Oct 30, 2024EF Hutton-BuyInitialise
Jun 26, 2024BTIGUnderperformUnderperformHold
Jun 26, 2024H.C. WainwrightBuyBuyHold
May 10, 2024H.C. WainwrightBuyBuyHold
Apr 02, 2024H.C. WainwrightBuyBuyHold
Nov 30, 2022Zacks Investment Research-BuyUpgrade
Row per page
Go to

Carisma Therapeutics's last stock rating was published by EF Hutton on Oct 30, 2024. The company Initialise its CARM rating from "null" to "Buy".

Carisma Therapeutics Financial Forecast

Carisma Therapeutics Revenue Forecast

Dec 28Sep 28Jun 28Mar 28Dec 27Sep 27Jun 27Mar 27Dec 26Sep 26Jun 26Mar 26Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Sep 21
Revenue---------------------$3.83M-$3.24M-
Avg Forecast$7.93M$7.55M$7.18M$6.83M$6.49M$6.18M$5.87M$5.59M$5.31M$5.05M$4.81M$4.57M$1.69M$1.69M$8.57M$1.69M$5.46M$5.47M$3.92M$4.40M$2.91M$1.19M$1.08M$3.73M$533.33K
High Forecast$9.16M$8.71M$8.29M$7.88M$7.50M$7.13M$6.78M$6.45M$6.14M$5.84M$5.55M$5.28M$1.95M$1.95M$9.89M$1.79M$6.78M$6.31M$3.92M$5.08M$3.36M$1.37M$1.25M$4.31M$533.33K
Low Forecast$7.05M$6.70M$6.38M$6.06M$5.77M$5.49M$5.22M$4.96M$4.72M$4.49M$4.27M$4.06M$1.50M$1.50M$7.61M$1.59M$4.59M$4.86M$3.92M$3.91M$2.58M$1.05M$960.31K$3.31M$533.33K
# Analysts1111111111111112311121111
Surprise %---------------------3.22%-0.87%-

Carisma Therapeutics's average Quarter revenue forecast for Dec 23 based on 2 analysts is $2.91M, with a low forecast of $2.58M, and a high forecast of $3.36M. CARM's average Quarter revenue forecast represents a -24.05% decrease compared to the company's last Quarter revenue of $3.83M (Sep 23).

Carisma Therapeutics EBITDA Forecast

Dec 28Sep 28Jun 28Mar 28Dec 27Sep 27Jun 27Mar 27Dec 26Sep 26Jun 26Mar 26Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Sep 21
# Analysts1111111111111112311121111
EBITDA---------------------$-22.34M-$-22.18M$63.12M
Avg Forecast$-4.76M$-4.53M$-4.31M$-4.10M$-3.90M$-3.71M$-3.52M$-3.35M$-3.19M$-3.03M$-2.88M$-2.74M$-1.02M$-1.02M$-5.14M$-1.02M$-3.28M$-3.28M$-2.35M$-2.64M$-1.74M$-712.00K$-648.60K$-2.24M$-320.00K
High Forecast$-4.23M$-4.02M$-3.83M$-3.64M$-3.46M$-3.29M$-3.13M$-2.98M$-2.83M$-2.69M$-2.56M$-2.44M$-902.12K$-902.12K$-4.57M$-956.85K$-2.75M$-2.91M$-2.35M$-2.34M$-1.55M$-632.51K$-576.19K$-1.99M$-320.00K
Low Forecast$-5.50M$-5.23M$-4.97M$-4.73M$-4.50M$-4.28M$-4.07M$-3.87M$-3.68M$-3.50M$-3.33M$-3.17M$-1.17M$-1.17M$-5.94M$-1.07M$-4.07M$-3.79M$-2.35M$-3.05M$-2.01M$-822.17K$-748.96K$-2.58M$-320.00K
Surprise %---------------------31.38%-9.91%-197.26%

1 analysts predict CARM's average Quarter EBITDA for Mar 23 to be $-2.24M, with a high of $-1.99M and a low of $-2.58M. This is -103.55% lower than Carisma Therapeutics's previous annual EBITDA (Sep 21) of $63.12M.

Carisma Therapeutics Net Income Forecast

Dec 28Sep 28Jun 28Mar 28Dec 27Sep 27Jun 27Mar 27Dec 26Sep 26Jun 26Mar 26Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Sep 21
# Analysts1111111111111112311121111
Net Income---------------------$-21.40M-$-24.64M$71.67M
Avg Forecast$-6.63M$-5.92M$-5.45M$-5.70M$-6.59M$-5.89M$-5.42M$-6.07M$-7.02M$-6.28M$-5.78M$-6.51M$-13.32M$-10.84M$-5.63M$-8.22M$-6.85M$-13.09M$-12.30M$-17.97M$-22.95M$-23.68M$-24.79M$-36.97M$-58.16M
High Forecast$-5.66M$-5.06M$-4.66M$-4.87M$-5.63M$-5.03M$-4.63M$-5.19M$-6.00M$-5.37M$-4.94M$-5.57M$-11.39M$-9.27M$-4.81M$-7.03M$-5.86M$-11.19M$-10.51M$-15.36M$-20.08M$-20.24M$-21.19M$-31.61M$-58.16M
Low Forecast$-7.96M$-7.12M$-6.55M$-6.84M$-7.91M$-7.07M$-6.51M$-7.30M$-8.43M$-7.54M$-6.94M$-7.82M$-16.00M$-13.02M$-6.76M$-9.87M$-8.23M$-15.72M$-14.77M$-21.58M$-26.23M$-28.44M$-29.77M$-44.41M$-58.16M
Surprise %---------------------0.90%-0.67%-1.23%

Carisma Therapeutics's average Quarter net income forecast for Mar 23 is $-36.97M, with a range of $-44.41M to $-31.61M. CARM's average Quarter net income forecast represents a -151.59% decrease compared to the company's last Quarter net income of $71.67M (Sep 21).

Carisma Therapeutics SG&A Forecast

Dec 28Sep 28Jun 28Mar 28Dec 27Sep 27Jun 27Mar 27Dec 26Sep 26Jun 26Mar 26Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Sep 21
# Analysts1111111111111112311121111
SG&A---------------------$6.62M-$9.57M$8.70M
Avg Forecast$6.36M$6.05M$5.75M$5.47M$5.20M$4.95M$4.71M$4.48M$4.26M$4.05M$3.85M$3.66M$1.36M$1.36M$6.87M$1.36M$4.38M$4.38M$3.15M$3.52M$2.33M$951.09K$866.40K$2.99M$368.36K
High Forecast$7.34M$6.98M$6.64M$6.32M$6.01M$5.72M$5.44M$5.17M$4.92M$4.68M$4.45M$4.23M$1.57M$1.57M$7.93M$1.43M$5.43M$5.06M$3.15M$4.07M$2.69M$1.10M$1.00M$3.45M$368.36K
Low Forecast$5.65M$5.37M$5.11M$4.86M$4.62M$4.40M$4.18M$3.98M$3.78M$3.60M$3.42M$3.26M$1.21M$1.21M$6.10M$1.28M$3.68M$3.89M$3.15M$3.13M$2.07M$844.90K$769.67K$2.66M$368.36K
Surprise %---------------------6.96%-3.20%23.62%

Carisma Therapeutics's average Quarter SG&A projection for Dec 23 is $2.33M, based on 2 Wall Street analysts, with a range of $2.07M to $2.69M. The forecast indicates a -64.81% fall compared to CARM last annual SG&A of $6.62M (Sep 23).

Carisma Therapeutics EPS Forecast

Dec 28Sep 28Jun 28Mar 28Dec 27Sep 27Jun 27Mar 27Dec 26Sep 26Jun 26Mar 26Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Sep 21
# Analysts1111111111111112311121111
EPS---------------------$-0.53-$-1.93$7.28
Avg Forecast$-0.16$-0.14$-0.13$-0.14$-0.16$-0.14$-0.13$-0.15$-0.17$-0.15$-0.14$-0.16$-0.32$-0.26$-0.14$-0.20$-0.17$-0.32$-0.30$-0.43$-0.55$-0.57$-0.60$-0.89$-1.40
High Forecast$-0.14$-0.12$-0.11$-0.12$-0.14$-0.12$-0.11$-0.12$-0.14$-0.13$-0.12$-0.13$-0.27$-0.22$-0.12$-0.17$-0.14$-0.27$-0.25$-0.37$-0.48$-0.49$-0.51$-0.76$-1.40
Low Forecast$-0.19$-0.17$-0.16$-0.16$-0.19$-0.17$-0.16$-0.18$-0.20$-0.18$-0.17$-0.19$-0.39$-0.31$-0.16$-0.24$-0.20$-0.38$-0.36$-0.52$-0.63$-0.68$-0.72$-1.07$-1.40
Surprise %---------------------0.93%-2.17%-5.20%

According to 1 Wall Street analysts, Carisma Therapeutics's projected average Quarter EPS for Mar 23 is $-0.89, with a low estimate of $-1.07 and a high estimate of $-0.76. This represents a -112.23% decrease compared to CARM previous annual EPS of $7.28 (Sep 21).

Carisma Therapeutics Peer Comparison by Price Target

TickerCompanyLast Closing PriceAvg Price TargetUpside/DownsideAvg Rating
HEPAHepion Pharmaceuticals$0.69$70.0010044.93%Buy
CARMCarisma Therapeutics$0.87$6.00589.66%Buy
IMMXImmix Biopharma$1.70$7.00311.76%Buy
CNSPCNS Pharmaceuticals$0.13$0.50284.62%-
ZURAZura Bio$3.15$10.00217.46%Buy
VECTVectivBio$16.87$18.006.70%Buy
EFTReFFECTOR Therapeutics-$5.50-Buy
PALIPalisade Bio$2.43$1.50-38.27%Buy

CARM Forecast FAQ

Is Carisma Therapeutics a good buy?

Yes, according to 3 Wall Street analysts, Carisma Therapeutics (CARM) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 3 'Buy' recommendations, accounting for 100.00% of CARM's total ratings.

What is CARM's price target?

Carisma Therapeutics (CARM) average price target is $6 with a range of $6 to $6, implying a 591.96% from its last price of $0.867. The data is based on 3 Wall Street analysts who provided a twelve-month price target estimate in the last three months.

Will Carisma Therapeutics stock go up soon?

According to Wall Street analysts' prediction for CARM stock, the company can go up by 591.96% (from the last price of $0.867 to the average price target of $6), up by 591.96% based on the highest stock price target, and up by 591.96% based on the lowest stock price target.

Can Carisma Therapeutics stock reach $1?

CARM's average twelve months analyst stock price target of $6 supports the claim that Carisma Therapeutics can reach $1 in the near future.

What are Carisma Therapeutics's analysts' financial forecasts?

Carisma Therapeutics's analysts financial forecasts for the fiscal year (Dec 2027) are as follows: average revenue is $24.13M (high $27.86M, low $21.43M), average EBITDA is $-14.477M (high $-12.86M, low $-16.717M), average net income is $-23.971M (high $-20.491M, low $-28.792M), average SG&A $19.34M (high $22.33M, low $17.18M), and average EPS is $-0.577 (high $-0.493, low $-0.693). CARM's analysts financial forecasts for the fiscal year (Dec 2028) are as follows: average revenue is $29.48M (high $34.04M, low $26.19M), average EBITDA is $-17.689M (high $-15.714M, low $-20.426M), average net income is $-23.701M (high $-20.26M, low $-28.468M), average SG&A $23.63M (high $27.28M, low $20.99M), and average EPS is $-0.571 (high $-0.488, low $-0.685).

Did the CARM's actual financial results beat the analysts' financial forecasts?

Based on Carisma Therapeutics's last annual report (Dec 2023), the company's revenue was $14.92M, beating the average analysts forecast of $8.91M by 67.53%. Apple's EBITDA was $-86.879M, beating the average prediction of $-5.343M by 1525.96%. The company's net income was $-86.879M, missing the average estimation of $-108M by -19.85%. Apple's SG&A was $29.52M, beating the average forecast of $7.14M by 313.66%. Lastly, the company's EPS was $-259, beating the average prediction of $-2.609 by 9832.28%. In terms of the last quarterly report (Sep 2023), Carisma Therapeutics's revenue was $3.83M, beating the average analysts' forecast of $1.19M by 222.50%. The company's EBITDA was $-22.344M, beating the average prediction of $-712K by 3038.20%. Carisma Therapeutics's net income was $-21.403M, missing the average estimation of $-23.68M by -9.62%. The company's SG&A was $6.62M, beating the average forecast of $951.09K by 596.04%. Lastly, the company's EPS was $-0.53, missing the average prediction of $-0.57 by -7.02%